Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $7.2 million during 4Q17 Positive Adjusted EBITDA of $2.4 million vs.

Lebanon will be the second Middle Eastern country to approve ILUVIEN   ATLANTA, February 5, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that product registration has been

ATLANTA, February 4th, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the three and twelve month periods ended December 31, 2018

Anticipates 2018 GAAP Net Revenue in Excess of $45 Million ATLANTA, January 7, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter

The U.A.E. becomes the first country in the Middle East to obtain pricing approval   ATLANTA, December 17, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had

Co-founder Dan Myers Named Non–Executive Chairman Additional Changes to the Executive Team   ATLANTA, November 29, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the company’s

ATLANTA, November 26, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Health Canada has approved ILUVIEN ® for the treatment of diabetic macular edema (DME).

ATLANTA, GA / ACCESSWIRE / November 9, 2018 /  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will be presenting at the following investor

Monday, November 5, 2018 7:45 PM Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ATLANTA, GA / ACCESSWIRE / November 5, 2018 / Alimera Sciences, Inc.

ATLANTA, October 23, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2018, after the close of the